Articles

Just a shot in the dark?

Cancer vaccines slow to catch on
Written byKimberely Sirk
| 7 min read

The bane of childhood—the recurring trek to a doctor'soffice to receive vaccinations—is now looked to as a promising approach topreventing and treating certain types of cancers. In fact, one of thosechildhood immunizations—the "hep b" vaccine given shortly after birth—hasprovided protection against liver cancer since 1981.

Cancer vaccines are medicines that fall under the categoryof biological response modifiers, which work by stimulating or restoring theimmune system's ability to fight invaders that make the body fall ill. Themedicines fall under two broad headings: prophylactic or preventive vaccines,and therapeutic or treatment vaccines.

Two types of cancer preventive vaccines are available in theUnited States, and two cancer treatment vaccines are in limited use. Othertreatment vaccines are being studied in labs across the nation.

A shot of preventionis worth a pound of cure

Currently, only vaccines to prevent the sexually transmittedhuman papillomavirus (HPV) and hepatitis B (HBV) are approved for use. The HPVvaccines Gardasil (Merck) or Cervarix (GlaxoSmithKline) are used to preventonly specific strains of the virus; those strains are thought to be responsiblefor the majority of cervical cancers. Gardasil also offers protection againsttwo additional types of HPV—those that are implicated in 90 percent of cases ofgenital warts in both men and women, but do not cause cervical cancer. Cervarixoffers protection against the two strains that indicate future cervical cancer,but the drug has shown additional promise in preventing infection from otherstrains.

Although the primary indication is to prevent cervicalcancer, recent recommendations suggest that better overall prevention could beachieved if young males also receive the HPV vaccine. The Gardasil vaccine isapproved for these indications in females and males ages nine to 26. Cervarixis approved for use in females ages nine to 25. The vaccines also offer someprotection against other types of genitourinary cancers.

HBV, or what's known as the "hep b" vaccine, works bypreventing chronic hepatitis infections that can lead to liver cancer.

Attacking cancerswith a needle

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.